Les nouveautés 2009 sur le cancer de la prostate : les points forts de l'ASTRO, l'EAU, l'ASCO et l'AUA

25 mars 2010

Auteurs : L. Salomon, M. Peyromaure, P. Mongiat-Artus, F. Roset, N. Gachignard, C. Bastide, P. Richaud, P. Beuzeboc, F. Cornud, V. Molinié, M. Soulié, A. Benchikh El Fegoun, Les membres du CC-AFU
Référence : Prog Urol, 2010, 20, S61, suppl. S1


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser


Andriole G., Bostwick D., Brawle O., Gomella L., Marberger M., Montorsi F., et al. Further analyses from the REDUCE prostate cancer risk reduction trial AUA 2009 ; abstract LBA1.
Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study N Engl J Med 2009 ;  360 : 1320-1328 [cross-ref]
Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., et al. Mortality results from a randomized prostatecancer screening trial N Engl J Med 2009 ;  360 : 1310-1319 [cross-ref]
Roobol M.J., Schröder F.H., Andriole G.L., Fleshner N.E. Defining men at increased risk of developing prostate cancer: evidence from a population-based screening cohort J Urol 2009 ;  181 : 747Abstract 2063.
Vickers A.J., Cronin A.M., Manjer J., Dahlin A., Bjartell A., Scardino P.T., et al. Prostate specific antigen level at age 60 and death from prostate cancer J Urol 2009 ;  181 : 59Abstract 163.
de la Taille A., Irani J., de Reijke T.M., Haese A. Can prostate cancer gene 3 (PCA3) predict initial biopsy outcome? J Urol 2009 ;  181 : 655Abstract 1816.
Hessels D., Smit F.P., Verhaegh G.W., Witjes J.A., Schalken J.A., Cornel E.B. Detection of TMPRSS2-ERG fusion transcripts and PCA3 in urinary sediments may improve diagnosis of prostate cancer EAU Meeting, Milan 2009 ; Abstract 279.
Groskopf J., Miick S., Kwon G.Y., Wixom C., Nigwekar P., Tadros Y., et al. Direct detection of TMPRSS2: ETS gene fusion mRNAs in prostatectomy tissue: prevalence and correlation with pathologic features EAU Meeting, Milan 2009 ; Abstract 283.
Kattan M.W., Wheeler T.M., Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 1999 ;  17 : 1499-1507
Stephenson A.J., Klein E.A., Kattan M.W., Han M., Partin A.W., Walsh P.C., et al. Predicting the long-term risk of prostate cancerspecific mortality after radical prostatectomy J Clin Oncol 2009 ;  27 : abstract 5007.
Antonarakis E.S., Trock B.J., Feng Z., Humphrey E.B., Carducci M.A., Partin A.W. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up J Clin Oncol 2009 ;  27 : abstract 5008.
Stark J.R., Perner S., Stampfer M.J., Sinnott J.A., Finn S., Eisenstein A.S., et al. Gleason Score and Lethal Prostate Cancer: Does 3+4=4+3 ? J Clin Oncol 2009 ;  27 : 21
Nelson J.B. The evolving presentation and natural history of prostate cancer: who should not be treated? J Clin Oncol 2009 ;  27 : 15s [cross-ref]
Glode L.M., Tangen C.M., Hussain M.H., Wood D.P., Swanson G.P., Quinn D.I., et al. Southwest Oncology Group S9921: Prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation J Clin Oncol 2009 ;  27 : abstract 5009.
Widmark A., Klepp O., Solberg A., Damber J.E., Angelsen A., Fransson P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 2009 ;  373 : 301-308 [cross-ref]
Mottet N.A., Goussard M., Loulidi S., Wolff J.M. Intermittent versus continuous maximal androgen blockade in metastatic (D2) prostate cancer patients. A randomized trial J Urol 2009 ;  181 : 233Abstract 645.
Lin D.D., Marks L.S., Morton R.A., Rodriguez D. Positive fracture réduction trial of Toremifene 80 mg in men on ADT demonstrates significant fracture risk in untreated placebo group J Urol 2009 ;  181 : 229Abstract 639.
Veverka K.A., Malkowicz B., Smith M., Morton R.A., Steiner M.S., et al. The effect of Toremifene citrate on BMD in men on ADT: A phase III clinical trial J Clin Oncol 2009 ;  27 : abstract 5055.
Saad F., Smith F.M., Egerdie B., Tammela T.L., Feldman R.A., Heracek J., et al. Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC) J Clin Oncol 2009 ;  27 : abstract 5056.
Scher H.I., Beer T.M., Higano C.S., Logothetis C., Anand A., Hirmand M., et al. Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC) J Clin Oncol 2009 ;  27 : abstract 151.
Reid A.H., Attard G., Danila D., Ryan C.J., Thompson E., Kheoh T., et al. A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts) J Clin Oncol 2009 ;  27 : abstract 5047.

© 2010 
Elsevier Masson SAS. Tous droits réservés.